These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36375775)

  • 1. Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections.
    Wang P; Liu D; Sun T; Zhang X; Yang J
    Int J Antimicrob Agents; 2022; 60(5-6):106693. PubMed ID: 36375775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Polymyxin B in Obese Patients for Resistant Gram-Negative Infections.
    Wang P; Zhang Q; Feng M; Sun T; Yang J; Zhang X
    Front Pharmacol; 2021; 12():754844. PubMed ID: 34880755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study.
    Tang T; Li Y; Xu P; Zhong Y; Yang M; Ma W; Xiang D; Zhang B; Zhou Y
    Crit Care; 2023 Apr; 27(1):164. PubMed ID: 37106370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration.
    Wang P; Xing H; Zhang F; Liu S; Lu Y; Zhang X; Yang J; Sun T
    Int J Antimicrob Agents; 2022 Jul; 60(1):106599. PubMed ID: 35526750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetic Modeling Using Polymyxin B Free Plasma Concentrations From Published Reports and Evaluation of Dosage Regimens Based on Monte Carlo Simulation in Critically Ill Patients.
    Zheng Y; Xu B; Chen S; Liu M; Huang H; Wang J; Wu X
    J Clin Pharmacol; 2023 Sep; 63(9):1036-1044. PubMed ID: 37125471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions.
    Yu XB; Jiao Z; Zhang CH; Dai Y; Zhou ZY; Han L; Wen X; Sheng CC; Lin GY; Pan JY
    Br J Clin Pharmacol; 2021 Apr; 87(4):1869-1877. PubMed ID: 33002196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics and clinical outcomes of polymyxin B in paediatric patients with multidrug-resistant Gram-negative bacterial infections.
    Wang PL; Liu P; Zhang QW; Yuan WH; Wang D; Zhang XJ; Yang J
    J Antimicrob Chemother; 2022 Oct; 77(11):3000-3008. PubMed ID: 35924405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm.
    Lakota EA; Landersdorfer CB; Nation RL; Li J; Kaye KS; Rao GG; Forrest A
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations.
    Xie J; Roberts JA; Lipman J; Cai Y; Wang H; Zhao N; Xu X; Yang S; Li Y; Zhang K
    Int J Antimicrob Agents; 2020 Jun; 55(6):105943. PubMed ID: 32184115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients.
    Miglis C; Rhodes NJ; Avedissian SN; Kubin CJ; Yin MT; Nelson BC; Pai MP; Scheetz MH
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal Empiric Polymyxin B Treatment of Patients Infected with Gram-Negative Organisms Detected Using a Blood Antimicrobial Surveillance Network in China.
    Wu X; Huang C; Wang H; Ji J; Ying C; Xiao Y
    Drug Des Devel Ther; 2021; 15():2593-2603. PubMed ID: 34168431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The population pharmacokinetics and dose optimization of polymyxin B in critically ill patients with or without extracorporeal membrane oxygenation.
    Ye Q; Wang Q; Chen W; Zhang R; Chen Z; Li P; Zhang X; Zhan Q; Wang C
    J Clin Pharm Ther; 2022 Oct; 47(10):1608-1618. PubMed ID: 35716048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients.
    Hanafin PO; Kwa A; Zavascki AP; Sandri AM; Scheetz MH; Kubin CJ; Shah J; Cherng BPZ; Yin MT; Wang J; Wang L; Calfee DP; Bolon M; Pogue JM; Purcell AW; Nation RL; Li J; Kaye KS; Rao GG
    Clin Microbiol Infect; 2023 Sep; 29(9):1174-1181. PubMed ID: 37217076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing use of colistin and polymyxin B in the critically ill.
    Nation RL; Li J
    Semin Respir Crit Care Med; 2007 Dec; 28(6):604-14. PubMed ID: 18095224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with/without continuous renal replacement therapy.
    Luo X; Zhang Y; Liang P; Zhu H; Li M; Ding X; Zhang J
    Eur J Pharm Sci; 2022 Aug; 175():106214. PubMed ID: 35609779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant
    Yu Z; Liu X; Du X; Chen H; Zhao F; Zhou Z; Wang Y; Zheng Y; Bergen PJ; Li X; Sun R; Fang L; Li W; Fan Y; Wu H; Guo B; Li J; Yu Y; Zhang J
    Front Pharmacol; 2022; 13():975066. PubMed ID: 36588676
    [No Abstract]   [Full Text] [Related]  

  • 18. Daily fluid intake as a novel covariate affecting the population pharmacokinetics of polymyxin B in patients with sepsis.
    Wang P; Liu S; Sun T; Yang J
    Int J Antimicrob Agents; 2024 Mar; 63(3):107099. PubMed ID: 38280575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults.
    Kispal B; Walker SAN
    Eur J Clin Pharmacol; 2021 Feb; 77(2):197-205. PubMed ID: 32975650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.
    Samtani MN; Flamm R; Kaniga K; Nandy P
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2360-4. PubMed ID: 20385857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.